High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study

References

• Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656. Doi:10.1056/NEJMra1413485
   PubMed Web of Science ®Google Scholar
• Pierri F, Dufour C. Management of aplastic anemia after failure of frontline immunosuppression. Expert Rev Hematol. 2019;12(10):809–819. Doi:10.1080/17474086.2019.1645003
   PubMed Web of Science ®Google Scholar
• Jing FM, Zhang XL, Meng FL, et al. Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO. Thromb Res. 2018;170:200–206. Doi:10.1016/j.thromres.2018.08.021
   PubMed Web of Science ®Google Scholar
• Panse J. [Diagnosis and therapy of aplastic anemia – update 2021]. Deutsche Medizinische Wochenschrift (1946). 2021;146(7):451–454. Doi:10.1055/a-1169-0902
   PubMedGoogle Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. Doi:10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23. Doi:10.1007/s12185-013-1382-0
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11–23. Doi:10.1056/NEJMoa2109965
   PubMed Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. Doi:10.1056/NEJMoa1613878
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(3):437–444. Doi:10.1200/JCO.2009.24.7999
   PubMed Web of Science ®Google Scholar
• Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EqoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4(3):e127–e136. Doi:10.1016/S2352-3026(17)30012-1
   PubMed Web of Science ®Google Scholar
• Dmytrijuk A, Robie-Suh K, Rieves D, et al. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park, NY). 2009;23(13):1171–1177.
   PubMed Web of Science ®Google Scholar
• Shirasugi Y, Ando K, Hashino S, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90(2):157–165. Doi:10.1007/s12185-009-0361-y
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846. Doi:10.1002/cncr.28663
   PubMed Web of Science ®Google Scholar
• Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol. 2017;8(5):159–174. Doi:10.1177/2040620717693573
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98(5):1339–1345. Doi:10.1182/blood.V98.5.1339
   PubMed Web of Science ®Google Scholar
• Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107(6):615–623. Doi:10.1007/s12185-018-2445-z
   PubMed Web of Science ®Google Scholar
• Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–228. Doi:10.1007/s12185-012-1124-8
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol. 2020;95(12):1542–1552. Doi:10.1002/ajh.25989
   PubMed Web of Science ®Google Scholar
• Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–1547. Doi:10.1182/blood-2014-06-581868
   PubMed Web of Science ®Google Scholar
• Arai Y, Jo T, Matsui H, et al. Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis. Haematologica. 2018;103(1):163–171. Doi:10.3324/haematol.2017.174615
   PubMed Web of Science ®Google Scholar
• Yang Y, Tang Z, Ji J, et al. Recombinant human thrombopoietin accelerates the recovery of platelet in patients With lower-risk myelodysplastic syndrome: A proof-of-concept study. Front Oncol. 2021;11:721764. Doi:10.3389/fonc.2021.721764
   PubMed Web of Science ®Google Scholar
• Mei H, Xu M, Yuan G, et al. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol. 2021;195(5):781–789. Doi:10.1111/bjh.17808
   PubMed Web of Science ®Google Scholar
• Zhang ML, Chen WS, Han B. [Evaluation of the efficacy of cyclosporin A combined with recombined human thrombopoietin for treating patients with non-severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(8):637–642.
   PubMedGoogle Scholar
• Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(12):712–718. Doi:10.1056/NEJM198203253061204
   PubMed Web of Science ®Google Scholar
• Wang JX, Zhang FC, Liu XQ, et al. [Expert consensus for diagnosis and treatment of thrombocytopenia in China]. Zhonghua nei ke za zhi. 2020;59(7):498–510.
   PubMedGoogle Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90–92. Doi:10.1016/j.ad.2019.05.009
   PubMed Web of Science ®Google Scholar
• Hosokawa K, Yamazaki H, Tanabe M, et al. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia. 2021;35(3):906–909. Doi:10.1038/s41375-020-0950-6
   PubMed Web of Science ®Google Scholar
• Bergamaschi G, Borrelli de Andreis F, Aronico N, et al. Anemia in patients with COVID-19: pathogenesis and clinical significance. Clin Exp Med. 2021;21(2):239–246. Doi:10.1007/s10238-020-00679-4
   PubMed Web of Science ®Google Scholar
• Tabata S, Hosoi H, Murata S, et al. Severe aplastic anemia after COVID-19 mRNA vaccination: causality or coincidence? J Autoimmun. 2022;126:102782. Doi:10.1016/j.jaut.2021.102782
   PubMed Web of Science ®Google Scholar
• Yang Y, Tang Z, Huang Y, et al. Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study. Blood Cancer J. 2023;13(1):74. Doi:10.1038/s41408-023-00845-3
   PubMed Web of Science ®Google Scholar